This case report describes a 78-year-old 
Introduction

Coronary spastic angina (CSA) is well treated with calcium antagonists and/or nitrates in most cases. However, despite the use of maximum doses of antianginal drugs, there are cases of refractory angina pectoris; some have been reported to be cured by mechanical interventions with coronary stents
or pharmacological interventions other than ordinary antianginal medications, including β1-adrenoceptor agonists (3) and corticosteroids (4) . The vascular endothelium is a multifunctional organ that plays an essential role in normal vascular physiology, and endothelial dysfunction may be a critical factor in the pathogenesis of CSA (5, 6) . In patients with CSA, antioxidant administration, in addition to conventional treatments, has beneficial effects for endothelial function (7) , the coronary vasomotor response to acetylcholine (8) and suppression of variant angina attacks (9) . It has been reported that angiotensin II stimulates the generation of vascular reactive oxygen species via NADH/NADPH oxidase activation (10) and that an angiotensin II type 1 receptor blocker (ARB), valsartan, improves endothelial vasomotor dysfunction through suppression of free radical production in a rabbit infarction model (11) . In addition, we previously reported that an ARB, candesartan, attenuates nitrate tolerance in patients with CSA (12) . Therefore i g u r e 1 . Co r o n a r y a n g i o g r a m o f t h e p a t i e n t . P a n e l s A a n d D s h o w t h e l e f t a n d r i g h t c o r o n a r y a r t e r i e s a t c o n t r o l . P a n e l s B a n d E s h o w t h o s e d u r i n g c o r o n a r y s p a s m i n d u c e d b y i n t r a c o r o n a r y i n j e c t i o n o f a c e t y l c h o l i n e . P a n e l s C a n d F s h o w t h o s e a f t e r i n t r a c o r o n a r y i n j e c t i o n o f i s o s o r b i d e d i n i t r a t e . Ar r o ws 1 ( p a n e l B ) a n d 3 ( p a n e l E ) i n d i c a t e t h e t o t a l o c c l u s i o n o f t h e l e f t c i r c u mf l e x b r a n c h a n d t h e r i g h t c o r o n a r y a r t e r y , r e s p e c t i v e l y . P a r e n t h e s i s 2 ( p a n e l B ) i n d i c a t e s d i f f u s e n a r r o wi n g o f t h e l e f t a n t e r i o r d e s c e n d i n g b r a n c h .
F i g u r e 2 . E l e c t r o c a r d i o g r a m o f t h e p a t i e n t .
T h e l e f t 3 p a n e l s a r e l i mb l e a d s a n d t h e r i g h t 3 p a n e l s a r e p r e c o r d i a l l e a d s . T h e l e f t r o ws i n b o t h s e t s o f 3 l e a d s we r e a t c o n t r o l ; t h e c e n t e r a n
d l e f t r o ws we r e d u r i n g a c e t y l c h o l i n e i n j e c t i o n i n t o t h e l e f t a n d r i g h t c o r o n a r y a r t e r i e s , r e s p e c t i v e l y .
sequent coronary spasm provocation test by intracoronary injection of acetylcholine (ACh) was done as reported before (13, 14) . The (Fig. 2) . These findings suggested that his angina was variant angina (15) although the ECG findings were obtained during just a (Fig. 3) . (16) and indirect AT2 stimulation effect such as vasodilation and nitric oxide increasing by the drug was more highly anticipated (17) . We speculate that angiotensin II type 1 blocking and antioxidative effects, and/or attenuation of nitrate tolerance were responsible for the beneficial effect of valsartan on CSA in this patient.
F i g u r e 3 . T h e u p p e r b a r g r a p h s h o ws t h e n u mb e r o f a n g i n a a t t a c k s b a s e d o n s y mp t o ms c o l l e c t e d f r o m t h e p a t i e n t ' s d i a r y d u r i n g t h e o b s e r v a t i o n p e r i o d i n t h i s c a s e r e p o r t . Co n s u mp t i o n o f g l y c e r i n e t r i n i t r a t e f l u c t u a t e d i n a c c o r d a n c e wi t h t h e n u mb e r o f a n g i n a a t t a c k s a n d v a r i e d i n v e r s e l y wi t h t h e d o s e o f v a l s a r t a n .
With the expectation of suppression of anginal attacks through improving endothelial function, oral administration of valsartan (80 mg/day) was given on a trial basis. After the use of 80 mg valsartan, the number of angina attacks and GTN use during next 4 weeks was decreased by 66%. Furthermore, angina attacks completely disappeared after increasing the dose of valsartan to 160 mg and he did not consume any GTN tablets during the 4-week period (Fig. 3). Valsartan was administered twice a day at the same time as diltiazem and isosorbide mononitrate. To confirm the effect of valsartan on his angina attacks, valsartan was discontinued during the next 4 weeks with his consent. During this period, angina attacks recurred at about 50% of the number in the first 4 weeks in the absence of valsartan (Fig. 3). Because his blood pressure response to 160 mg of valsartan was acceptable and the drug was believed to effectively control his angina, valsartan was added to his regular prescription list. During the 4 weeks after valsartan was used on a regular basis, he had 1 angina attack and consumed 2 GTN tablets.
Discussion
This is the first report demonstrating that an ARB may be effective in suppressing angina attacks in a patient with severe, drug-refractory CSA. Of all ARBs, valsartan was used in this case because its AT1 selectivity is high enough
Drug-refractory coronary spastic angina
Coronary spasm plays an important role in the pathogene-sis of not only CSA but also ischemic heart disease in general (18) . Multivessel coronary spasm is thought to be one of the most severe forms of CSA because simultaneous multivessel coronary spasm is associated with severe and extensive myocardial ischemia (14) . Multivessel coronary spasm is often associated with refractory angina (19) (1, 2) , β1-adrenoceptor agonists (3) and corticosteroids (4) . In this case, the daily administration of 160 mg valsartan was effective in relieving angina that was refractory to conventional medications for coronary spasm.
Manner of expression of valsartan effects on coronary spastic angina
In the case, the effects of valsartan on coronary spasm could be dose dependent because 160 mg of valsartan was more effective to inhibit anginal attacks due to coronary spasm than 80 mg. However, 160 mg of valsartan after the temporary cessation of the drug failed to completely inhibit the attacks as observed with the previous administration of the same dose. This means that it takes some time to express the valsartan effects although acute effects were also observed to some extent. In this way, manner of valsartan effects on coronary spasm could be comprised of both acute and chronic effects. (7, 8) and suppress anginal attacks (9) in patients with CSA. An antioxidant action of ARBs has also been recognized in recent years (10, (24) (25) (26) 
Mechanisms of acute effects of valsartan on coronary spastic angina
